What Is ProQR Therapeutics N.V. (PRQR) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, ProQR Therapeutics N.V.'s intrinsic value is estimated at $1.08, suggesting the stock is overvalued at its current price of $1.77. With 8 out of 8 models flagging downside (-38.9% average return), the market may be pricing in unsustainable growth. Notably, PWERM sees the most upside at -15.3% (fair value: $1.50), while ML-RIV is the most conservative at -97.8% ($0.04). The spread between these extremes — +82.5% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About PRQR?
8 of 13 models are currently active for PRQR. All 8 active models suggest the stock trades above fair value. The Bayesian DCF estimates PRQR's intrinsic value at $1.04, implying -41.2% downside from the current price. See which stocks rank higher →
How Does PRQR Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, PRQR ranks #186 by Quality of Company score. CirclFi's QOC score of 5.2/10 evaluates 32 fundamental signals. A score of 5.2 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, ProQR Therapeutics N.V. operates in a sector where FDA approval probability is a critical driver of valuation. Investors evaluating PRQR should weigh these sector-specific dynamics alongside our model-derived fair values.
Is PRQR a Value Trap?
CirclFi's Value Trap algorithm assigns PRQR a score of 30/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
8 of 13 models are active for ProQR Therapeutics N.V.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, ProQR Therapeutics N.V.'s fundamental quality profile registers 5.2/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +82.5% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PRQR valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PRQR's 8 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad